Here we treated the cells with cisplatin (DDP), a chemotherapy drug commonly used in the treatment of NPC.[20] The results showed that after treating the cells with different concentrations of DDP, the chemotherapy drug sensitivity of NPC cells SUNE‐1, HNE‐1 and S18 with TMEM52B knockdown was significantly enhanced (Figure8A), while the drug resistance of TMEM52B‐P18 and TMEM52B‐P20 overexpressed NPC cells HONE‐1, HK‐1, and S18 to DDP was significantly enhanced (Figure 8B). This evidence concerns the gene TMEM52B and nasopharyngeal carcinoma.